These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 9726030)

  • 1. Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients.
    Feelders RA; Vreugdenhil G; Eggermont AM; Kuiper-Kramer PA; van Eijk HG; Swaak AJ
    Eur J Clin Invest; 1998 Jul; 28(7):520-7. PubMed ID: 9726030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
    Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL
    J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.
    Gérain J; Liénard D; Pampallona S; Baumgartner M; Rüegg C; Buurman WA; Eggermont A; Lejeune F
    Cytokine; 1997 Dec; 9(12):1034-42. PubMed ID: 9417816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors.
    Schienk S; Liénard D; Gerain J; Baumgartner M; Lejeune FJ; Chiquet-Ehrismann R; Rüegg C
    Int J Cancer; 1995 Nov; 63(5):665-72. PubMed ID: 7591283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
    Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
    J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
    Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
    Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.
    De Vries MR; Borel Rinkes IH; Swaak AJ; Hack CE; Van De Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Eggermont AM
    Eur J Clin Invest; 1999 Jun; 29(6):553-60. PubMed ID: 10354218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of recovery from the euthyroid sick syndrome induced by tumor necrosis factor alpha in cancer patients.
    Feelders RA; Swaak AJ; Romijn JA; Eggermont AM; Tielens ET; Vreugdenhil G; Endert E; van Eijk HG; Berghout A
    Metabolism; 1999 Mar; 48(3):324-9. PubMed ID: 10094108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion.
    Liénard D; Lejeune FJ; Ewalenko P
    World J Surg; 1992; 16(2):234-40. PubMed ID: 1561804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
    Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
    J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage.
    Stam TC; Swaak AJ; de Vries MR; ten Hagen TL; Eggermont AM
    Ann Surg Oncol; 2000 May; 7(4):268-75. PubMed ID: 10819366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of recombinant tumour necrosis factor (rTNF-alpha) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-alpha administration in isolated limb perfusions in cancer patients.
    Swaak AJ; Lienard D; Schraffordt Koops H; Lejeune FJ; Eggermont AM
    Eur J Clin Invest; 1993 Dec; 23(12):812-8. PubMed ID: 7511535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
    Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
    J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs.
    Eggimann P; Chioléro R; Chassot PG; Lienard D; Gerain J; Lejeune F
    Chest; 1995 Apr; 107(4):1074-82. PubMed ID: 7705119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
    Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: changes in transferrin uptake, iron handling and ferritin mRNA.
    Fahmy M; Young SP
    Biochem J; 1993 Nov; 296 ( Pt 1)(Pt 1):175-81. PubMed ID: 8250840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of circulating bone marrow-derived VEGFR-2+ progenitor cells in isolated limb perfusion with or without rhTNF-α.
    Nowak K; Jachol N; Rafat N; Joas E; Beck GCh; Hohenberger P
    Ann Surg Oncol; 2013 Oct; 20(11):3694-701. PubMed ID: 22948772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unidirectional upregulation of the synthesis of the major iron proteins, transferrin-receptor and ferritin, in HepG2 cells by the acute-phase protein alpha1-antitrypsin.
    Graziadei I; Weiss G; Bohm A; Werner-Felmayer G; Vogel W
    J Hepatol; 1997 Oct; 27(4):716-25. PubMed ID: 9365048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma.
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
    J Cell Biochem; 1994 Sep; 56(1):52-61. PubMed ID: 7806592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.